Researchers identify a key 'brake' of the immune response

February 04, 2002

When the body is exposed to a foreign substance, such as a virus or bacteria, the immune system responds in an elaborate process by making cells and agents that fight off the invaders.

But sometimes physicians want to be able to turn off the immune response, such as during bone marrow or organ transplants to prevent the host from rejecting the donor tissue. On the other hand, doctors would like to boost the immune response against malignant cells and HIV-infected cells to help fight cancer and AIDS.

Now scientists at Columbia University College of Physicians & Surgeons and elsewhere report they have identified a key pair of molecules, called ILT3 and ILT4, that could help clinicians precisely modulate the immune response to help treat a variety of diseases. The molecules are the first to be characterized on antigen presenting immune cells, called dendritic cells, to function as a brake for the immune response. Antigens are molecules, such as proteins from viruses or even from the body's own tissue, that can elicit an immune response.

The findings are being reported Jan. 27 in the online version of Nature Immunology and in the February issue of the publication.

Led by Dr. Nicole Suciu-Foca, professor of clinical pathology, the researchers provide evidence for how increasing the amount of ILT3 and ILT4 on dendritic cells could create tolerance to foreign tissues, such as donor tissue or bone marrow. Their results also suggest that somehow decreasing the amount of ILT3 and ILT4 on these cells might allow the body to better fight AIDS and cancer cells.

ILT3 and ILT4 on dendritic cells function as a brake for the immune system, shutting off the immune response and then creating a state of tolerance to antigens, which can be foreign or derived from the body itself, explains Dr. Suciu-Foca. To shut down the immune response, the body presses its "foot" harder on the brake pedal to boost ILT3 and ILT4 activity in the dendritic cells. To enhance the immune response, the body lowers the ILT3 and ILT4 activity.

In the study, the investigators showed how other cells of the immune system, the T-suppressor cells, are responsible for slowing down the activity of the dendritic cells. Dendritic cells present to T cells, including T suppressor cells, the specific antigen against which the immune response had been initiated.

In the study, the researchers showed in cell culture how increasing the activity of ILT3 and ILT4 on dendritic cells could make the immune system tolerant to antigens. They also analyzed the blood of heart transplant recipients and showed that those who did not reject donor hearts had T- suppressor cells that induced the activity of ILT3 and ILT4 in donor dendritic cells. The results show that the heart recipients without rejection had T-suppressor cells that had been primed to suppress a response to foreign hearts.

The findings of the study also have implications for type I diabetes and other autoimmune diseases, Dr. Suciu-Foca says. In autoimmune disease, the immune system attacks normal body tissue rather than being tolerant of it. Enhancing activity of ILT3 and ILT4 in dendritic cells, which present the target antigen in such patients, might help affected patients suppress the immune response against their own tissues.

Dr. Suciu-Foca and her colleagues are now investigating the possible use of ILT3 and ILT4 to treat patients with AIDS, cancer, or transplants.

The research was supported by grants from the National Institutes of Health and the Interuniversity Organ Transplantation Consortium in Rome, Italy.
-end-


Columbia University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.